Submitted by Jeffrey Lake on Fri, 02/10/2017 - 1:59pm What is your profession? * What is your profession? What is your preferred method of online learning about recent advances in the management of solid tumors? (more than 1 answer possible) * Scientific publications Roundtable/panel discussions by experts in the field Case studies presented by experts in the field Webcasts by experts in the field International congress highlights Interactive E-learning modules Infographics/visual summaries Other... What is your profession? What is your preferred method of online learning about recent advances in the management of solid tumors? (more than 1 answer possible) Other... How aware are you of the clinical profile of newly emerging targeted therapy options for hematologic malignancies? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware How aware are you of the clinical profile of newly emerging immunotherapy options for hematologic malignancies? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware How often do you request molecular profiling of PD-1/PD-L1 expression levels in your patients with hematologic malignancies? * Always Very often Occasionally Not very often Never N/A How often do you request molecular profiling of PD-1/PD-L1 expression levels in your patients with hematologic malignancies? * Always Very often Occasionally Not very often Never N/A How familiar are you with the impact that CAR-T cell therapies could have on the treatment of hematologic cancers? * Very familiar, I have a complete understanding of the impact that emerging treatments could have Familiar, I have a basic understanding of the impact that emerging treatments could have I have heard of the impact that emerging treatments could have, but cannot recall it Not familiar How aware are you of emerging and promising treatment options for non-Hodgkin lymphoma (NHL)? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware How confident are you in choosing the optimal long-term treatment plan for your patients with multiple myeloma (MM) in terms of retaining disease control while maintaining quality of life? * Very confident Confident Reasonably confident, I would like to learn more Not very confident, I should learn more N/A How aware are you of the clinical profile of newly emerging treatment options for MM? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware How confident are you in choosing the optimal long-term treatment plan for your patients with myeloproliferative neoplasm (MPN)? * Very confident Confident Reasonably confident, I would like to learn more N/A How aware are you of the clinical profile of newly emerging treatment options for MPN? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware How aware are you of emerging and promising treatment options for acute myeloid leukemia (AML)? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware How confident are you in determining the optimal treatment plan for patients with lower-risk myelodysplastic syndrome (MDS)? * Very confident Confident Reasonably confident, I would like to learn more Not very confident, I should learn more N/A How aware are you of emerging and promising treatment options for acute lymphoblastic leukemia (ALL), including adolescent and young adult patients? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name Email: Leave this field blank
